A Study of Tirzepatide (LY3298176) in Healthy Lactating Females

Inclusion Criteria: * Participants who are overtly healthy females as determined by medical evaluation * Female participants who delivered normal-term infant (at least 37 weeks gestation) and are at least 6 weeks postpartum at the time of screening * Body mass index (BMI) between 18.5 and 40.0 kilograms per meter squared (kg/m²), inclusive * Female participants who has well-established lactation and is breastfeeding her infant. Note: Breastfeeding must be discontinued prior to the administration of tirzepatide on Day 1 and not resumed for the remaining duration of the study until a follow-up visit (or for total of 29 days after tirzepatide dosing for participants who discontinue early). Exclusion Criteria: * Have a history of inadequate lactation (for multiparous females who have previously breastfed) * Have confirmed type 1 or type 2 diabetes mellitus * Regularly use known drugs of abuse or show positive findings on drug screen